RXi Pharmaceuticals Appoints Robert Bitterman and Keith Brownlie to Board of Directors

WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (OTCBB: RXII.OB) today announced that Robert Bitterman and Keith Brownlie have been appointed to the Company’s Board of Directors. Mr. Bitterman and Mr. Brownlie both bring extensive industry experience that will be instrumental to supporting RXi’s growth and development initiatives.

Back to news